This page shows the latest Tredaptive news and features for those working in and with pharma, biotech and healthcare.
this year after disappointments such as the failure of cholesterol drug Tredaptive (extended-release niacin/laropiprant).
The company suffered another R&D setback recently when it dropped development of another phase III project – cardiovascular treatment Tredaptive ER (laropiprant and niacin) – after disappointing results in the HPS-2
including the failure of cholesterol drug Tredaptive (extended-release niacin/laropiprant).
The company recently dropped cholesterol drug Tredaptive (extended-release niacin/laropiprant) after disappointing results in a trial, which showed it was no more effective than statins but increased the risk of
But the use of new, separate accounts for medicines and medical devices seems logical, given the differences in audience for a recall of Merck Sharp &Dohme's Tredaptive versus that for
The EMA's confirmation now seals Tredaptive's fate, and the regulator recommended patients taking the medicine should make a non-urgent appointment with their doctor to discuss treatment options. ... Outside Europe, Merck has already said it does not
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
This included a global release available at the press event and distribution over the wires, a glossy media guide to cardiovascular disease, fact sheets on heart disease, Merck’s drug Tredaptive
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...